Copper (64Cu) oxodotreotide

Copper (64Cu) oxodotreotide
INN: Copper (⁶⁴Cu) oxodotreotide

Names
Trade names	Detectnet
Other names	Copper Cu 64 dotatate
IUPAC name 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)
Clinical data
Drug class	Radioactive diagnostic agent
Main uses	Positron emission tomography (PET) of neuroendocrine tumors (NETs)
Side effects	Nausea, vomiting, flushing
Pregnancy category	US: N (Not classified yet)
Routes of use	Intravenous
Legal
License data	US DailyMed: Detectnet
Legal status	US: ℞-only
Chemical and physical data
Formula	C65H88CuN14O19S2
Molar mass	1497.16 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O.[Cu+2]
InChI InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0 Key:IJRLLVFQGCCPPI-NVGRTJHCSA-L

Copper (⁶⁴Cu) oxodotreotide, sold under the brand name Detectnet, is a radioactive diagnostic agent used in positron emission tomography (PET) of neuroendocrine tumors (NETs). Specifically it is used in adults with somatostatin receptor positive disease. It is given by injection into a vein.

Common side effects include nausea, vomiting, and flushing. Other side effects include radiation exposure and allergic reactions. It interacts with somatostatin analogs. Use during pregnancy may harm the baby. It works by binding to somatostatin receptor, particularly subtype 2 receptors.

Copper (⁶⁴Cu) oxodotreotide was approved for medical use in the United States in 2020. In the United States it costs about 3,900 USD for a vial as of 2022.

Medical uses

Dosage

It is typically used at a dose of 148 MBq (4 mCi).

History

The U.S. Food and Drug Administration (FDA) approved copper ⁶⁴Cu dotatate based on data from two trials that evaluated 175 adults.

Trial 1 evaluated adults, some of whom had known or suspected NETs and some of whom were healthy volunteers. The trial was conducted at one site in the United States (Houston, TX). Both groups received copper ⁶⁴Cu dotatate and underwent PET scan imaging.

Trial 2 data came from the literature-reported trial of 112 adults, all of whom had history of NETs and underwent PET scan imaging with copper ⁶⁴Cu dotatate. The trial was conducted at one site in Denmark. In both trials, copper ⁶⁴Cu dotatate images were compared to either biopsy results or other images taken by different techniques to detect the sites of a tumor. The images were read as either positive or negative for presence of NETs by three independent image readers who did not know participant clinical information.

See also

• Copper-64
• DOTA-TATE

External links

Identifiers:	ATC code: None CAS Number: 1426155-87-4 PubChem CID: 124220636 UNII: N3858377KC KEGG: D11882

• "Copper dotatate Cu-64". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-05-21. Retrieved 2022-10-20.
• "copper Cu 64 dotatate injection safety data sheet" (PDF). Curium US LLC. 15 March 2020. Archived (PDF) from the original on 27 October 2020. Retrieved 20 October 2022.